EGF and cancer: Attempts to stimulate invadopodia formation in of two of these nine “invadopodia-negative” cancer cell lines (SKOV-3 and OVCAR-3) using EGF (10 and 30 ng/mL), see also [49] or YAP/TAZ suppression (see below) did not trigger enhanced invadopodia formation or gelatin degradation in these cells (Supplementary Fig. S3).